“New” Plan B Emails Say FDA’s “Novel” Concerns Were Not Novel – Waxman
This article was originally published in The Tan Sheet
Executive Summary
Internal emails suggest FDA began addressing legal issues pertaining to "dual marketing" of Plan B in early 2004; these documents could strengthen the Center for Reproductive Rights' suit against the agency over the delay in considering OTC status for the drug
You may also be interested in...
FDA Topsiders Must Testify In Plan B Case – Judge
The Center for Reproductive Rights will be allowed to take depositions from certain FDA "senior decision-makers" in their suit against the agency over decisions related to emergency contraceptive Plan B
FDA Disagrees With GAO’s “Unusual” Findings Regarding Plan B Decision
Reports from FDA officials vary as to the timing of the decision not to approve Barr's emergency contraceptive Plan B for over-the-counter sale, GAO's investigation into the application process reveals (see chart: "1Brief Timeline of Major Plan B Events Related to the Initial OTC Switch Application").
Investigation Into McClellan Plan B Memos Sought By House Democrats
The GAO investigation into FDA's decision-making process that led to the Plan B switch rejection has raised questions as to whether FDA violated federal records management laws